Business
Krystal Biotech Announces Change in Financial Leadership
PITTSBURGH, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"PITTSBURGH, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced the appointment of Kathryn Romano as chief accounting officer, based in its headquarters in Pittsburgh, PA. Krystal also announced that Tony Riley has resigned as chief financial officer, effective Feb. 22, 2020.\n \"As our corporate needs continue to evolve, particularly as we develop our research, clinical manufacturing and regulatory footprint in Pittsburgh, Kate brings important financial leadership experience to manage the growth of our company,\" said Krish S. Krishnan, chairman and chief executive officer of Krystal. \"It is my pleasure to welcome Kate to Krystal’s senior management team. We thank Tony for his contributions over the years and wish him the very best moving forward.\" Ms. Kathryn Romano was most recently corporate controller at CNX Resources Corporation. Prior to joining CNX, Ms. Romano was the corporate controller of Rice Energy from January 2013 until the company was acquired by EQT in November 2017, staying on to assist the company through the transition until March 2018. Prior to joining Rice Energy, she worked in a variety of accounting and auditing roles at Black Box Corporation and Deloitte. Ms. Romano is a Certified Public Accountant and holds a bachelor's degree in accounting from Penn State University. About Krystal BiotechKrystal Biotech, Inc. (NASDAQ: KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal, including but not limited to statements about the development of Krystal’s product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of bercolagene telserpavec (“B-VEC”) and KB105, the clinical utility of B-VEC and KB105 and Krystal’s plans for filing of regulatory approvals and efforts to bring B-VEC and KB105 to market, the market opportunity for and the potential market acceptance of B-VEC and KB105, plans to pursue research and development of ...